chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Day one was headache as expected and right arm pain. Day two I had bad headache (9) joint pain in my shoulder and hips, loud ringing ears. shortness of breathe, left lung pain. This repeated for three days so I tested by BP and found it to be 160/130. Past day 3 I started with adrenaline spikes where heart would race up and I felt like hulk and blood pressure spikes out of the random. 5/24/21, I saw my family doctor and since my BP was so random high and then low she did not want to give me meds since it could drops too low at time. For my difficulty breathing and lung pain she gave me an prescription inhaler. As of today I still have the ringing left ear, shoulder joint pain like a pin stuck in it and unable to raise over my head without using my left arm to support, high BP on average 140/132. 167/151, 126/89, 122/91,110/87, 126/84 are some examples. These at the lowest is 10+ point higher than my normal range of 120s over 70s. Headache continues but may be due to the higher than normal BP.
Pt states he developed neck pain and side pain on the side of the body in which the flu shot was given. Lft arm.
Developed right-sided  headache with facial weakness and numbness on April 19. Blurred vision and ptosis, inability to hold liquids in right side of mouth, irregular smile, and nose bleeds. CT of head same day was negative for any acute findings. Evaluated by optometrist on April 22 and referred to other eye specialist. Evaluated on April 27 by specialist and diagnosed with Bell's palsy. Prescribed steroids and acyclovir. Family reports patient's facial weakness has improved significantly, smile is equalizing and patient is able to blink and move muscles in forehead. Still has some residual symptoms at this time.
This is a spontaneous report from a contactable consumer via a Pfizer sales representative. A 18-years-old male patient of an unspecified ethnicity received TRUMENBA, intramuscular on an unspecified date at 0.5 ml, single dose. The patient medical history was none, the patient was healthy and the patient's did not receive any concomitant medications. The patient previously took human papilloma vaccine and experienced syncope. The patient experienced fainted on an unspecified date with outcome of unknown. Follow-up (15JAN2016): Follow-up attempts completed. No further information expected.
INR of 12.5 and he was hospitalized; A spontaneous report was received on 04 Mar 2021 from a consumer concerning, a 56-year-old, male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced international normalized ratio (INR) of 12.5 and was hospitalized.   The patient's medical history, as provided by the reported included back pain and muscle spasms. Concomitant medications included hydrocodone bitartrate, paracetamol, cefixime and warfarin (blood thinner) was reported.   On 24 Feb 2021, prior to the onset of events, the patient received their first of two planned doses of mRNA-1273 (Batch Number: 001A21A) in the left arm for prophylaxis of COVID-19 infection.   On 01 Mar 2021, after the vaccination, the patient's international normalized ratio (INR) was increased from 3.5 to 12.5 which resulted in hospitalization. Treatment information included vitamin K and blood transfusion.   Action taken with mRNA-1273 in response to the event was not reported.     The outcome of the event, international normalized ratio (INR) of 12.5, was considered unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Watch notified me of AFIB at 1:30 am on 7 NOV while I was up late reading my kindle.  I then used the ECG function on the watch to take an ECG, which indicated AFIB (my previous ECGs were all normal sinus rhythm).  I received several notifications throughout the day and repeated the ECGs which confirmed AFIB - and called my primary care physician on Monday, 8 NOV.  The NP did an EKG and confirmed that I was in AFIB and told me to drive to the ER, where I was admitted - they administered a blood thinner (Heparin) that evening.  Administered echocardiogram on 9 NOV, discharged early afternoon with 2 new prescriptions:  apixaban twice daily and metoprolol twice daily diagnosis was AFIB with RVR. When I completed my weekly post COVID booster survey, I didn't say that I thought my AFIB was caused by the vaccine and no one at the doctor's office or hospital mentioned the vaccine as a possible cause.
temp @ home approx 8PM 104R; between 8-9PM t105 R observed x 3hrs; temp relieved w/advil; coughing-no infect-diarrhea 3 days later x 24hrs;
Information has been received from a physician's assistant concerning a female with seafood allergy and no pertinent medical history who in approximately 1997 was vaccinated with the three dose series of RECOMBIVAX HB. There were no concomitant medications. In approximately 2002, the patient had a negative titer. The three dose series was repeated again in approximately 2002, and a titer after that series was again negative. The outcome was not recovered. Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested.
This spontaneous report was received from a healthcare worker (also reported as office manager) refers to multiple unspecified patients of unknown demographics. No relevant medical history of the patients was reported. On unspecified dates the multiple unspecified patients were vaccinated with (Oka/Merck) VARIVAX (strength, dose, route, site of administration and lot number were not reported). There were no concomitant medications reported. It was reported that the multiple unspecified patients were administered with (Oka/Merck) VARIVAX that was stored improperly on unknown dates. There were no adverse effects reported.  It was unspecified whether the patients had sought any medical attention. There was no product quality complaint involved.   Follow up information has been received from office manager, who stated she may call back or fax information as it become available. Also report that M-M-R II was not mentioned in the original call, but did experience a temperature excursion. No further information was available at that time.   Follow up information as received from office manager refers to a 12 months old patient. On 04-JUN-2014 the patient was vaccinated with a dose of improperly stored (Oka/Merck) VARIVAX (lot # J012818, expiration date: 10-OCT-2015) (strength, dose, route and site of administration were not reported.  This is one of several reports from the same source. Additional information has been requested.
Came to the clinic with rapid HR. Wanted second dose. Taken to triage before vaccinated.  Vital Signs: BP 125/80 HR 130 Resp 20 O2Sat 97 Skin Signs: Warm and Dry  Circulation: Cap refill <2sec  12:18 PM HR 101 Sat 95 12:25 PM HR 113 Sat 98 Initial Treatment: Had patient lay down. HR decreased 106. Up walking with Dr. at 12:15 PM without incident. EMS called per Dr., Lt. and Major. Sitting in chair awaiting EMS and 12 lead EKG.  12:25 PM EMS arrived.  Vital Signs: 123/81 HR 103 Resp 22 O2Sat 98  12:35 PM  EKG leads removed  Vital Signs: HR 102 O2Sat 96  Skin Signs: Warm and dry  Circulation: Cap refill <2sec  Respiratory: Breath sound clear bilaterally  12:35 PM  Advised to talk to her MD  Notes: Patient was seen and examined by Medical Doctors. Vital signs and patient were clinically stable. We recommended with follow up with MD. Disposition: Home by Self
This spontaneous case reported by a consumer (subsequently medically confirmed), and describes the occurrence of pruritus (face itching), erythematous rash (red rash on face) and face swelling (swelling in the face) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. March 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. March 2021, patient experienced pruritus (face itching), erythematous rash (red rash on face) and face swelling (swelling in the face). At the time of the report, pruritus (face itching), erythematous rash (red rash on face) and face swelling (swelling in the face) resolved. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. No concomitant medications reported. Treatment included: allergy medicine. Patient is fine now. She went to a doctor to get medicine for her side effects. It took about two weeks before the side effects went away. Most recent follow-up information incorporated above included: On May 18, 2021: Outcome of all the events updated from unknown to recovered.
Was prescribed medications for Shingles by healthcare provider. Was diagnosed with Cerebral Palsy; has been seen by neurologist.
Fever over 100 degrees, muscle aches and joint pains, general weakness and malaise, at approximately 20 hours after injection, until about 30 hours after.
Patient developed chest pain seven days following vaccination. Reported to local emergency department and was diagnosed with pericarditis. Treated with Colchicine and Ibuprofen with resolution of symptoms.
Immediately when the vaccine was injected I felt a sharp pain go down my arm a few inches from the injection site.  The injection was placed much higher than I've had previously.  My arm has been very painful in the time since (now 3 weeks).  It hurts in the shoulder joint, and in the biceps tendon.  It is very stiff and painful at night and in the morning, and even once I get it moving it is still very painful during the day.  Pain relievers don't work.  I have been applying heat per my primary care doctor's recommendation, but it is not getting  better.
BODY ACHES; VOMITING TWICE; BODY CHILLS; NAUSEA; This spontaneous report received from a consumer concerned a female of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested.  No concomitant medications were reported. On an unspecified date, the subject experienced body aches, vomiting twice, body chills, and nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the body chills, body aches, nausea and vomiting twice was not reported. This report was non-serious.
Child developed eczema on entire body, vomited, bled rectally after consuming Dairy through breastmilk. This has never happened prior to vaccine. He developed and maintained a fever almost immediately which lasted for 48 hours. He was grumpy, listless, and in pain.
I got my first covid 19 injection on Thursday (2/25) at around 11:30 am, and after about 17 minutes later, I began to have some numbness and tingling around my lips. It lasted about 20 minutes and went away, and I've been fine since.
Minutes after taking the shot he got dizzy and nausea when he was still sitting there. It subsided after a few and the he left. Around 9pm the same day he started feeling bad and he stated running a real high fever 100.5 and had chills, he took a real hot shower trying to warm up which didn't work. He took a 500mg bare aspirin and the fever finally broke after an hour. Slight body aches. An hour later he started itching real bad all over and little red bumps popped up all over his body. Started having body aches and chest pains. Took Benadryl and about an hour the itching stopped. Woke up the next morning and everything was gone away but since then he has had continuous chest pains and joint pains in his knees
Client called, reported 2 days after vaccine given, injection site reddened (2 in) with pink raised area (4-5 in) down arm towards elbow. No fever, no pain, has headaches (normal for her), arm "felt weird" warm to touch. Explained if it got worse or not improving, seek medical attention. Arm back to normal in 1-2 days.
Patient called 5/12/21 stating has been nauseous every day, starting 1 day after receiving the second Moderna shot.  She is taking nausea medicine several times per day to keep from vomiting.  Patient states she is also susceptible to low blood sugar events that cause nausea as well.  I counseled her that 2 of her medications can cause nausea as can increased anxiety.  I also counseled her to contact her primary care provider and make an appointment to be checked out.
I experienced sudden complete hearing loss and tinnitus in my left ear, 7 weeks after my last covid-19 vaccination.  I had no other hearing issues with myself or my family history.
Tachycardia, hypertension, whooshing/rushing sound in ears when change in head position occurs.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 51-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09Nov2022 as dose 5 (booster), single (Lot number: GJ3277) at the age of 51 years, in right arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 23Mar2021 as dose 1, single (Lot number: EP7534), in right arm, on 13Apr2021 as dose 2, single (Lot number: EW0161), in right arm, on 13Sep2021 as dose 3 (booster), single (Lot number: FE3592), in right arm and on 11Apr2022 as dose 4 (booster), single (Lot number: FYGG43), in right arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Mar2023, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical course: Patient was being treated with paxlovid from 18Mar2023 to 22Mar2023 for COVID-19.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300133332 same patient, different drug/event;
Gave patient dose of Fluarix quad, patient was fine standing and talking after receiving vaccine. Within two minutes patient fainted, face first. Patient was examined for injuries and was found to have bruising to the right forehead, and blood on gums, teeth were not loose. Patient sat in chair, and reported he was fine. Patient was given ice and water, and monitored for 15 minutes.
This spontaneous report as received from a Registered Nurse (RN) refers to a patient of unknown age and gender. The patient's medical history included herpes zoster (shingles). The patient was vaccinated with a dose of ZOSTAVAX (dose, route, lot number and expiration date were not reported) "every year" since an unspecified date. There was no concomitant medication provided. No adverse effect reported. The reporter also inquired if should ZOSTAVAX ever be given as a repeat dose, said every 5 years. As the reporter recently heard that it was no longer given as a one-time only dose. This is one of two reports received from the same reporter. Additional information has been requested.
Later that night I developed significant ataxia, fever and a significant headache.  It felt as if I was paralytic.  I treated it with ibueprophen and tylenol.  I was given a liter of fluid because I felt dehydrated which did make me feel better and the symptoms lasted about 6hrs but the headache and chills lasted about 24 hr and symptoms subsided after that.
1. Acute hypoxemic respiratory failure due to COVID-19   2. Acute hypoxemic respiratory failure  3. Type 2 myocardial infarction  4. History of polycythemia vera  5. Elevated brain natriuretic peptide (BNP) level  6. Elevated d-dimer
This spontaneous report was received from a pharmacist that was also de father of the patient, and refers to a 9 week old male patient. At age 4 weeks, the patient started a intolerance to milk products and was switched to formula with lower lactose a week ago. Before vaccination the patient took acetaminophen. On 06-NOV-2018,  the patient was vaccinated with ROTATEQ, oral for prophylaxis (dose, lot number and expiration date were not reported). On 07-NOV-2018, the patient experienced an increase drooling and vomited a couple times. No treatment was given and no overdose. At the time of report, the outcome of vomiting and drooling was reported as not recovered/not resolved. The causal relationship between the aforementioned events and vaccination with ROTATEQ was not reported.
Pt given a ZOSTAVAX immunization. Pt not > 50 yrs old.
This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's medical history or concurrent conditions were not reported. On an unknown dates, the patient was vaccinated with a dose of M-M-R II and RECOMBIVAX HB (dosage information, lot numbers and expiration dates were not informed) both for prophylaxis. Information regarding concomitant medication was not provided. It was reported that the patient developed increased anxiety lasting for an unspecified duration of time. The reporter did not indicate if the increased anxiety had resolved. There was no product quality complaint involved. At the time of reporting, the outcome of anxiety was unknown. The causality assessment between anxiety and therapy with M-M-R II and RECOMBIVAX HB was not provided. Additional information is not expected, since the physician cannot be contacted.
10cm diameter, indurated, tender, erythematous area lt tricep area x 7-9 days;
LOCALIZED PAIN; FELT COLD, CHATTERING, AND CHILLS; HEADACHE; MUSCLE ACHES; FEVER; LACK OF APPETITE; QUEASY; FELT EXHAUSTED; DIZZY AND ROOM FEELS LIKE ITS SPINNING; This spontaneous report received from a patient concerned a 50 year old female. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 043A21A, and batch number: 043A21A expiry: 21-JUN-2021) dose was not reported, administered on 03-APR-2021 to Left Arm for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced localized pain. On APR-2021, the subject experienced felt cold, chattering, and chills. On APR-2021, the subject experienced headache. On APR-2021, the subject experienced muscle aches. On APR-2021, the subject experienced fever. On APR-2021, the subject experienced lack of appetite. On APR-2021, the subject experienced queasy. On APR-2021, the subject experienced felt exhausted. On APR-2021, the subject experienced dizzy and room feels like its spinning. Treatment medications included: ibuprofen, and paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the localized pain, felt cold, chattering, and chills, headache, muscle aches, fever, lack of appetite, queasy, felt exhausted and dizzy and room feels like its spinning was not reported. This report was non-serious.
not able to eat; light headed; high blood pressure; nauseous; arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm was sore), DECREASED APPETITE (not able to eat), DIZZINESS (light headed), HYPERTENSION (high blood pressure) and NAUSEA (nauseous) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Type 2 diabetes mellitus. Concomitant products included SEMAGLUTIDE (OZEMPIC) for Type 2 diabetes mellitus.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, the patient experienced PAIN IN EXTREMITY (arm was sore). On 28-Feb-2021, the patient experienced DECREASED APPETITE (not able to eat), DIZZINESS (light headed), HYPERTENSION (high blood pressure) and NAUSEA (nauseous). At the time of the report, PAIN IN EXTREMITY (arm was sore), DECREASED APPETITE (not able to eat), DIZZINESS (light headed), HYPERTENSION (high blood pressure) and NAUSEA (nauseous) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medications provided by the reporter.
Loss of taste; Loss of smell; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 24-May-2021 and was forwarded to Moderna on 24-May-2021.    This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (Loss of taste) and ANOSMIA (Loss of smell) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033G21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 on 01-Jan-2021.    On 16-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-May-2021, the patient experienced AGEUSIA (Loss of taste) and ANOSMIA (Loss of smell). At the time of the report, AGEUSIA (Loss of taste) and ANOSMIA (Loss of smell) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Jan-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication and treatment information were not reported.
Intense stomach distress; pain and diarrhea x 6 days. Intense itching-arms, abdomen, neck, back, legs, headache x 6 days. Joint pain-increased loss of sense of taste-lasting 12 days. Swollen cervical lymph nodes-bilateral-still generally felt awful-fluish x 6 days.
Covid rebound. Tested negative 11Jun2022 Symptoms started again 18Jun2022 tested positive 19Jun2022; Covid rebound. Tested negative 11Jun2022 Symptoms started again 18Jun2022 tested positive 19Jun2022; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 01Mar2021 as dose 1, single (Lot number: EN6202), on 22Mar2021 as dose 2, single (Lot number: EP7534) and on 14Oct2021 as dose 3 (booster), single (Lot number: 301358A) at the age of 62 years for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: PROZAC; WELLBUTRIN.  The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Covid rebound. Tested negative 11Jun2022 Symptoms started again 18Jun2022 tested positive 19Jun2022". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (11Jun2022) Negative; (19Jun2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19. Concomitant medication(s) in 2 weeks included PROZAC and WELLBUTRIN. The patient had no known alleriges. The patient took Paxlovid for COVID 19 Treatment. The treatment start date was reported as 07Jun2022 and stop date was 10Jun2022.
Fussiness, red, inflamed, diffused, hot at injection site, bilateral thighs. Apply ice pack to site and Motrin every 6 hrs.
Headache, Myalgia, Arthralgia,  joint pain was limited to both wrists, elbows, shoulders and neck  Narrative:  I took Advil for 72 hours (2/5/21 to 2/7/21) to minimize the joint pain  and headache. However, the joint pain (both wrists, elbows, shoulders and neck)  and headache returned on 2/15/21 and lasted continuously until 2/19/21. It was  treated with OTC Advil to address the joint pain and headache.   Other Relevant History:
Fever to 103.2 with shaking chills and bad headache. Two and a half hours later developed diffuse itching and a hive of the left arm (mother is a dermatologist).